SEC 13F Intelligence

Highvista Strategies LLC / SYRE

Highvista Strategies LLC’s Spyre Therapeutics Inc Position

Does Highvista Strategies LLC own Spyre Therapeutics Inc (SYRE)? Yes — 146.3K shares worth $7M (+2.04% of its 13F portfolio) as of Q1 2026, down from 188.2K shares the prior filed quarter.

Position Value
$7M
Q1 2026
Shares
146.3K
% of Portfolio
+2.04%
Quarters Held
10
currently held

Position History SYRE

Reported value by quarter
Q4 ’23: $12MQ4 ’23Q1 ’24: $6MQ2 ’24: $3MQ2 ’24Q3 ’24: $3MQ4 ’24: $2MQ4 ’24Q1 ’25: $2MQ2 ’25: $2MQ2 ’25Q3 ’25: $4MQ4 ’25: $6MQ4 ’25Q1 ’26: $7Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026146.3K$7M+2.04%
Q4 2025188.2K$6M+1.59%
Q3 2025215.7K$4M+0.89%
Q2 2025112.8K$2M+0.62%
Q1 202595.2K$2M+0.59%
Q4 202495.2K$2M+0.82%
Q3 2024105.4K$3M+1.07%
Q2 2024113.5K$3M+0.98%
Q1 2024154.4K$6M+2.09%
Q4 2023577.6K$12M+4.51%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Highvista Strategies LLC’s full portfolio or all institutional holders of SYRE.